Our results thereby revealed that low pretreatment serum BChE was a novel prognostic biomarker for PFS, CSS, and OS in patients with LACC and early cervical cancer with lymph node metastases, independent of possible confounding factors. The gene discussed is BCHE; the disease is metastatic malignant neoplasm in the lymph nodes.